Impaired myelopoiesis and survival of granulocytes on A1 knockdown. (A) Representative dot blots of flow cytometric analysis of peripheral blood of mice of the indicated genotypes using antibodies to identify Mac-1⁺Gr-1⁻ monocytes/macrophages and Mac-1⁺Gr-1⁺ granulocytes, respectively, are shown. Numbers refer to percentages of region analysis. (B) The composition of myeloid cells in the bone marrow, spleen, and blood of WT, TREA1 single-transgenic, and the different eGFP fractions (−, +, ++) from DT mice is shown. Data are mean ± SEM of n = 4 to 8 animals per genotype. ANOVA followed by Fisher PLSD posthoc test: *P ≤ .05, compared with WT or single-transgenic controls; **P ≤ .01, compared with WT or single-transgenic controls. Gr1^high granulocytes were sorted from the bone marrow of (C) WT, the Venus⁺, or Venus⁻ pool of bone marrow cells from VVA1.1 or VVA1.2 mice. Alternatively, granulocytes were isolated from (D) WT, TREA1 single-transgenic mice, or the eGFP⁻, eGFP⁺, or eGFP⁺⁺ fraction of DT mice. Cells were put in culture without further treatment. Viability was assessed by 7-amino-actinomycin D exclusion in a flow cytometer. Bars represent mean ± SD of 4 mice per genotype. ANOVA followed by Fisher PLSD posthoc test: *P ≤ .05, compared with WT or single-transgenic controls; **P ≤ .01, compared with WT or single-transgenic controls.